Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
IMNM · Why this verdict
Why Immunome (IMNM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Immunome is a cash-burning pre-revenue biotech with quality far below minimum standards and a recent string of earnings misses, but the price target implies approximately 72% upside and the risk/reward ratio is approximately 19.5-to-1, creating a highly speculative asymmetric setup contingent on single-program clinical execution.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's near-term prospects are concentrated in a single clinical program, varegacestat, creating binary outcome risk where a clinical setback would eliminate the primary basis for the bull case. Bear case | Varegacestat reaches a meaningful clinical milestone within 12 months, reducing execution risk and moving toward a potential data readout. | →Stable |
| CounterFocused single-program biotechs can allocate capital and management attention more efficiently, potentially accelerating development timelines compared to companies spreading resources across multiple early-stage programs. | ||
The two most recent reported quarters were both misses — the latest by 32.8% and the preceding quarter by 19.6% — following an in-line quarter and a single beat, indicating a worsening trend in meeting consensus expectations. Earnings | Average quarterly EPS surprise improves above -10% over the next 2 reported quarters, signaling a stabilization in execution. | →Stable |
| CounterFor a pre-revenue biotech, EPS misses primarily reflect cash burn rate volatility; consensus estimates on R&D spend are notoriously imprecise, and misses need not signal any deterioration in the underlying clinical or commercial trajectory. | ||
Free cash flow is negative at roughly 3,470% of revenue, indicating the company is consuming capital at a rate vastly exceeding its current revenue base and is entirely dependent on external financing to sustain operations. Quality breakdown | FCF burn rate as a percentage of revenue remains above 1,000% over the next 4 reported quarters, confirming the structural nature of the capital dependency. | →Stable |
| CounterPre-clinical and clinical-stage biotechs are structurally expected to burn cash well in excess of revenue; the current burn rate may be appropriate given the clinical investment required, and the company's liquidity position indicates adequate near-term runway. | ||
Analysts project roughly 98% upside from current levels and the risk/reward ratio is approximately 19.5-to-1 in favor of buyers, offering an asymmetric return profile where the potential gain is large relative to a defined near-term downside. Sentiment breakdown | The share price appreciates toward analyst consensus targets over 12 months as clinical catalysts reduce uncertainty and close the gap to analyst targets. | →Stable |
| CounterHigh short interest of 17% and an elevated put/call ratio of 2.44 reflect informed participants actively positioned against the stock; analyst optimism at early-stage biotechs frequently overstates commercial probability, and the wide spread between current price and target may narrow through target cuts rather than price appreciation. | ||
The company's near-term prospects are concentrated in a single clinical program, varegacestat, creating binary outcome risk where a clinical setback would eliminate the primary basis for the bull case.
→StableBear case
- Expectation
- Varegacestat reaches a meaningful clinical milestone within 12 months, reducing execution risk and moving toward a potential data readout.
CounterFocused single-program biotechs can allocate capital and management attention more efficiently, potentially accelerating development timelines compared to companies spreading resources across multiple early-stage programs.
The two most recent reported quarters were both misses — the latest by 32.8% and the preceding quarter by 19.6% — following an in-line quarter and a single beat, indicating a worsening trend in meeting consensus expectations.
→StableEarnings
- Expectation
- Average quarterly EPS surprise improves above -10% over the next 2 reported quarters, signaling a stabilization in execution.
CounterFor a pre-revenue biotech, EPS misses primarily reflect cash burn rate volatility; consensus estimates on R&D spend are notoriously imprecise, and misses need not signal any deterioration in the underlying clinical or commercial trajectory.
Free cash flow is negative at roughly 3,470% of revenue, indicating the company is consuming capital at a rate vastly exceeding its current revenue base and is entirely dependent on external financing to sustain operations.
→StableQuality breakdown
- Expectation
- FCF burn rate as a percentage of revenue remains above 1,000% over the next 4 reported quarters, confirming the structural nature of the capital dependency.
CounterPre-clinical and clinical-stage biotechs are structurally expected to burn cash well in excess of revenue; the current burn rate may be appropriate given the clinical investment required, and the company's liquidity position indicates adequate near-term runway.
Analysts project roughly 98% upside from current levels and the risk/reward ratio is approximately 19.5-to-1 in favor of buyers, offering an asymmetric return profile where the potential gain is large relative to a defined near-term downside.
→StableSentiment breakdown
- Expectation
- The share price appreciates toward analyst consensus targets over 12 months as clinical catalysts reduce uncertainty and close the gap to analyst targets.
CounterHigh short interest of 17% and an elevated put/call ratio of 2.44 reflect informed participants actively positioned against the stock; analyst optimism at early-stage biotechs frequently overstates commercial probability, and the wide spread between current price and target may narrow through target cuts rather than price appreciation.
Per-dimension breakdown
Quality
1.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -3470% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.5 |
| Price target | 9.9 |
| erm sentiment | 4.9 |
- ▸Analyst upside: 72%
Insider
4.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 5.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $1,024,613 (0.046% of mkt cap)
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.3 |
| growth rank | 5.0 |
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.2 |
| support resistance | 4.1 |
| 52w position | 5.0 |
Risk (lower is worse)
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 0.0 |
| volatility | 2.4 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 3.1 |
| debt equity | 7.2 |
- ▸High short interest justified: 17%
- ▸High IV: 91%
- ▸Above max pain $15
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.4>=5.5
- ASYMMETRY:3.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
3.50
Upside
+49.8%
Downside
14.2%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 2.07>1.3, MCap $2.2B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 8.0, and Momentum at 6.4; the weakest are Quality at 1.7, Catalyst at 2.8, and Risk (lower is worse) at 3.4. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 3.50 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company's near-term prospects are concentrated in a single clinical program, varegacestat, creating binary outcome risk where a clinical setback would eliminate the primary basis for the bull case.
Trip ifActive late-stage clinical programs grow to more than 1, with a second program initiating Phase 2 or later within 2 calendar quarters.
- P2The two most recent reported quarters were both misses — the latest by 32.8% and the preceding quarter by 19.6% — following an in-line quarter and a single beat, indicating a worsening trend in meeting consensus expectations.
Trip ifAverage quarterly EPS surprise exceeds 0% for 2 consecutive reported quarters.
- P3Free cash flow is negative at roughly 3,470% of revenue, indicating the company is consuming capital at a rate vastly exceeding its current revenue base and is entirely dependent on external financing to sustain operations.
Trip ifFCF burn compresses to less than 1,000% of revenue for 2 consecutive reported quarters.
- P4Analysts project roughly 98% upside from current levels and the risk/reward ratio is approximately 19.5-to-1 in favor of buyers, offering an asymmetric return profile where the potential gain is large relative to a defined near-term downside.
Trip ifAnalyst consensus price target falls below $22.00 for 2 consecutive months.